Dr. Michael Pollack and Dr. Vamsee Pamula founded the company in 2004 and remain engaged full time with the company as co-CTO’s. Vamsee and Michael developed the core technology while completing their doctorates and post doctoral research at Duke University’s Pratt School of Engineering. The company is led by an experienced CEO, Richard West, who joined ALL in 2005. Rich has 15 year’s experience as a CEO and a cumulative 30 years in business and product development management. Since our founding ALL has focused on improving the capabilities and manufacturability of our core technology – digital microfluidics. Below, we list a few of our recent accomplishments: • ALL has been recognized by both Frost and Sullivan (Lab-on-a-Chip Company of the Year) and the Wall Street Journal (Technology Innovation Award) for its groundbreaking, disruptive technology and its progress in demonstrating its utility. • ALL has demonstrated – with performance comparable to or better than traditional systems – sample preparation, immunoassays, PCR, enzymatic assays, clinical chemistry, and DNA sequencing on its lab-on-a-chip platform. • ALL has created a talented and engaged team that includes senior executives in manufacturing, product development, human resources, and quality and regulatory affairs. The company has also developed numerous value-adding academic collaborations and an active advisory board. • ALL has implemented its lab-on-a-chip technology using low cost, manufacturable printed circuit board technology and has invested in facilities and equipment to scale up to high volume. • ALL has assembled a comprehensive intellectual property portfolio in the area of droplet-based digital microfluidics. The company owns or controls over 50 issued patents, has over 200 active patent filings and has made several strategic acquisitions and in-licensing deals. • ALL has signed collaborative product development and commercialization agreements with four commercial partners, including NuGEN® Technologies, Inc. in genomics sample preparation. These have significantly added to the company’s funding and product pipeline